Primary EBV infection and hypersensitivity to mosquito bites:a case report

正Dear Editor,Hypersensitivity to mosquito bites(HMB)is primarily seen in children and adolescents in Asia and Central America.HMB may be related to the reactivation of Epstein-Barr virus(EBV)in infected natural killer(NK)cells and is directly associated with chronic active EBV infection(CAEBV)and NK/T-cell leukemia/lymphoma.     

Hamstring antagonist moment estimation using clinically applicable models: Muscle dependency and synergy effects.

The purpose of this study was to examine whether prediction of antagonist moment (M(flx)) of the hamstrings using clinically applicable models depends on the muscles examined. Nine healthy males performed maximal isometric knee extension and flexion contractions at 0 degrees , 45 degrees and 90 degrees angles. Calibration knee flexion efforts were also performed at different levels of intensity. The resulting electromyographic (EMG) - moment curves were fitted using polynomial equations which were then used to estimate M(flx) from the antagonist EMG. Analysis of variance designs showed that the M(flx) predicted using the biceps femoris EMG was not significantly different compared with those predicted using the semitendinosus EMG data (p>0.05). Further, prediction of M(flx) using the EMG of both muscles or a combination of EMGs and architectural properties reduced estimation error but did not provide significantly different predicted values compared with the simpler single-muscle EMG - moment models (p<0.05). It appears that M(flx) prediction using the present EMG - moment model is not muscle specific. Prediction using models which combine EMG data and anatomic parameters of the hamstring muscle components yielded more accurate estimates and therefore their use to examine co-contraction levels is recommended.     

Matrix metalloproteinase inhibitors as anticancer agents

The important role of matrix metalloproteinases (MMPs) in the process of carcinogenesis is well established. However, despite very promising activity in a plethora of preclinical models, MMP inhibitors (MMPIs) failed to demonstrate a statistically significant survival advantage in advanced stage clinical trials in most human malignancies. Herein, we review the implication of MMPs in carcinogenesis, outline the pharmacology and current status of various MMPIs as anticancer agents and discuss the etiologies for the discrepancy between their preclinical and clinical evaluation. Finally, strategies for effective incorporation of MMPIs in current anticancer therapies are proposed.